Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers in chemotherapy

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7206-7220

  Jain, Vikas ^a   Swarnakar, Nitin K ^a   Mishra, Prabhat R ^b   Verma, Ashwni ^b   Kaul, Ankur ^c   Mishra, Anil K ^c   Jain, Narendra K ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Anticancer efficacy; Liquid crystalline nanoparticles; Paclitaxel; PEGylation; Pharmacoscintigraphy; SAXS

Indexed keywords

ANTICANCER EFFICACY; CRYSTALLINE NANOPARTICLES; PACLITAXEL; PEGYLATION; PHARMACOSCINTIGRAPHY; SAXS;

CELL CULTURE; CHEMOTHERAPY; CRYSTALLINE MATERIALS; DRUG DELIVERY; TECHNETIUM;

TUMORS;

ALCOHOL; COUMARIN; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; GLYCEROL OLEATE; HYDROTROPE; LIQUID CRYSTALLINE NANOPARTICLE; MACROGOL 2000; NANOCARRIER; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE; POLOXAMER; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; EHRLICH ASCITES TUMOR; ERYTHROCYTE COUNT; FEMALE; GAMMA SCINTIGRAPHY; HEMOCOMPATIBILITY; HYDROLYSIS; ISOTOPE LABELING; LEUKOCYTE COUNT; LIQUID CRYSTAL; LYMPHOCYTE; MALE; MICROSCOPY; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLARIZATION MICROSCOPY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; X RAY CRYSTALLOGRAPHY; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CRYOELECTRON MICROSCOPY; CRYSTALLIZATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; GLYCERIDES; HEMOLYSIS; LIQUID CRYSTALS; MALE; MICE; NANOPARTICLES; NANOTECHNOLOGY; PACLITAXEL; POLYETHYLENE GLYCOLS; RABBITS; RATS; SCATTERING, RADIATION; TECHNETIUM; TIME FACTORS;

MUS;

EID: 84864310354     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.056     Document Type: Article

References (57)

1. Arbuck S.G., Christian M.C., Fisherman J.S., Cazenave L.A., Sarosy G., Suffness M., et al. Clinical development of taxol. J Natl Cancer Inst Monogr 1993, 15:11-24.
2. Lee S.C., Kim C., Kwon I.C., Chung H., Jeong S.Y. Polymeric micelles of poly (2-ethyl-2-oxazoline)-block-poly(epsilon-caprolactone) copolymer as a carrier for paclitaxel. J Control Release 2003, 89:437-446.
3. Agueros M., Zabaleta V., Espuelas S., Campanero M.A., Irache J.M. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release 2010, 145:2-8.
4. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
5. Maranhão R.C., Tavares E.R., Padoveze A.F., Valduga C.J., Rodrigues D.G., Pereira M.D. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. Atherosclerosis 2008, 197:959-966.
6. ® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 2005, 59:177-187.
7. Alani A.W.G., Bae Y., Rao D.A., Kwon G.S. Polymeric micelles for the pH- dependent controlled, continuous low dose release of paclitaxel. Biomaterials 2010, 31:1765-1772.
8. Feng S.S., Mu L., Win K.Y., Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 2004, 11:413-424.
9. Lee J.S., Feijen J. Biodegradable polymersomes as efficient nanocarriers for controlled paclitaxel delivery. J Control Release 2010, 148:15-16.
10. Chen C., Cai G., Zhang H., Jiang H., Wang L. Chitosan-poly(epsilon-caprolactone)-poly(ethylene glycol) graft copolymers: synthesis, self-assembly, and drug release behavior. J Biomed Mater Res A 2011, 96:116-124.
11. Luzzati V., Husson F. The structure of the liquid-crystalline phases of lipid-water systems. J Cell Biol 1962, 12:207-219.
12. Gustafsson J., Ljusberg-Wahren H., Almgren M., Larsson K. Cubic lipid-water phase dispersed into submicron particles. Langmuir 1996, 12:4611-4613.
13. Spicer P.T., Hayden K.L., Lynch M.L., Ofori-Boateng A., Burns J.L. Novel process for producing cubic liquid crystalline nanoparticles (Cubosomes). Langmuir 2001, 17:5748-5756.
14. Boyd B.J., Whittaker D.V., Khoo S.M., Davey G. Hexosomes formed from glycerate surfactants-formulation as a colloidal carrier for irinotecan. Int J Pharm 2006, 318:154-162.
15. Lynch M.L., Ofori-Boateng A., Hippe A., Kochvar K., Spicer P.T. Enhanced loading of water-soluble actives into bicontinuous cubic phase liquid crystals using cationic surfactants. J Colloid Interface Sci 2003, 260:404-413.
16. Drummond C.J., Fong C. Surfactant self-assembly objects as novel drug delivery vehicles. Curr Opin Colloid Interface Sci 2000, 4:449-456.
17. Qui H., Caffrey M. Lyotropic and thermotropic phase behaviour of hydrated monoacylglycerols: structure characterisation of monovaccenin. J Phys Chem B 1998, 10:24819-24829.
18. Barauskas J., Landh T. Phase behaviour of the phytantriol/water system. Langmuir 2003, 19:9562-9565.
19. Abraham T., Hato M., Hirai M. Glycolipid based cubic nanoparticles: preparation and structural aspects. Coll Surf B Biointer 2004, 35:107-117.
20. Swarnakar N., Jain V., Dubey V., Mishra D., Jain N.K. Enhanced oromucosal delivery of progesterone via hexosomes. Pharm Res 2007, 24:2223-2230.
21. Rizwan S.B., Assmus D., Boehnke A., Hanley T., Boyd B.J., Rades T., et al. Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines. Eur J Pharm Biopharm 2011, 79:15-22.
22. Barauskas J., Cervin C., Jankunec M., Spandyreva M., Ribokaite K., Tiberg F., et al. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes. Int J Pharm 2010, 391:284-291.
23. Gabizon A., Shameeda H., Zalpisky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006, 16:175-183.
24. Allen T.M., Mehra T., Hansen C., Chin Y.C. Stealth liposomes: and improved sustained release system for 1-beta-D arabinofuranosylcy-tosine. Cancer Res 1992, 52:2431-2439.
25. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 2010, 49:6288-6308.
26. Maeda H., Wua J., Sawaa T., Matsumurab Y., Horic K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
27. Pasut G., Veronese F.M. Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci 2007, 32:933-961.
28. Rosevear F.B. The microscopy of the liquid crystalline neat and middle phases of soaps and synthetic detergents. J Am Oil Chem Soc 1954, 31:628-639.
29. Lee J., Kellaway I.W. Buccal permeation of [d-Ala, d-Leu] enkephalin from liquid crystalline phases of glyceryl monooleate. Int J Pharm 2000, 195:35-38.
30. Nguyen T., Hanley T., Porter C., Larson I., Boyd B. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically relevant media. J Pharm Pharmacol 2010, 62:844-855.
31. Pedersen J.S. A flux- and background-optimized version of the NanoSTAR small-angle X-ray scattering camera for solution scattering. J Appl Crystallogr 2004, 37:369-380.
32. ICH Harmonised tripartity guideline. Validation of analytical procedures: text and methodology Q2 (R1) 2005, IFPMA, Geneva.
33. Du Z., Pan S., Yu Q., Li Y., Wen Y., Zhang W., et al. Paclitaxel-loaded micelles composed of folate-poly(ethylene glycol) and poly(benzyl l-glutamate) diblock copolymer. Colloids Surf A Physicochem Eng Aspects 2010, 353:140-148.
34. Koziara J.M., Lockman P.R., Allen D.D., Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumor. J Control Release 2004, 99:259-269.
35. Mayer A., Vadonb M., Rinnera B., Novaka A., Wintersteigerc R., Fröhlicha E. The role of nanoparticle size in hemocompatibility. Toxicology 2009, 258:139-147.
36. Agashe H.B., Dutta T., Garg M., Jain N.K. Investigations on the toxicological profile of functionalized fifth-generation poly(propylene imine) dendrimer. J Pharm Pharmacol 2006, 58:1491-1498.
37. Gupta U., Dwivedi S.K., Bid H.K., Konwar R., Jain N.K. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int J Pharm 2010, 393:185-196.
38. Starek A. Studies on the nature of hemolytic effect induced by ethylene glycol alkyl ethers. Acta Pol Pharm Drug Res 2008, 65:421-425.
39. Jain A.K., Swarnakar N.K., Godugu C., Singh R.P., Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011, 32:503-515.
40. Jain S., Mathur R., Das M., Swarnakar N.K., Mishra A.K. Synthesis, pharmacoscintigraphic evaluation and antitumor efficacy of methotrexate-loaded, folate-conjugated, stealth albumin nanoparticles. Nanomedicine 2011, 6:1733-1754.
41. 13C NMR investigation on the internal structure of "Cubosomes" Langmuir 2001, 17:3917-3922.
42. Reddy L.H., Sharma R.K., Chuttani K., Mishra A.K., Murthy R.S.R. Etoposide incorporated tripalmitin nanoparticles with different surface charge: formation, characterization, radiolabeling and bio-distribution studies. AAPS J 2004, 6:1-10.
43. Danhier F., Lecouturier N., Vroman B., Jerome C., Marchand-Brynaert J., Feron O., et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009, 133:11-17.
44. van Vlerken L.E., Vyas T.K., Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 2007, 24:1405-1414.
45. Corinna B., Regina R., Roland W. Interaction of the anticancer agent Taxol™ (Paclitaxel) with phospholipid bilayers. J Biomed Mater Res 1998, 46:141-149.
46. Burt H.M., Zhang X., Toleikis P., Embree L., Hunter W.L. Development of copolymers of poly(D, L,-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf B Biointer 1999, 16:161-171.
47. Ooya T., Lee J., Park K. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release 2003, 93:121-127.
48. Huh K.M., Lee S.C., Cho Y.W., Lee J., Jeong J.H., Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release 2005, 101:59-68.
49. Lasic D.D. Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J Control Release 1997, 48:203-222.
50. Chang C.M., Bodmeier R. Binding of drugs to monoglyceride-based drug delivery systems. Int J Pharm 1997, 147:135-142.
51. Nguyen T.H., Hanley T., Porter C.J.H., Boyd B.J. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. J Control Release 2011, 153:180-186.
52. Shah M.H., Paradkar A. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme. Int J Pharm 2005, 294:161-171.
53. Caboi F., Amico G.S., Pitzalis P., Monduzzi M., Nylander T., Larsson K. Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior. Chem Phys Lipids 2001, 109:47-62.
54. Neto C., Aloisi G., Baglioni P., Larsson K. Imaging soft matter with the AFM. J Phys Chem B 1999, 103:3896-3899.
55. Makino K., Umetsu M., Goto Y., Nakayama A., Suhara T., Tsujii J., et al. Interaction between charged soft microcapsules and red blood cells: effects of PEGylation of microcapsule membranes upon their surface properties. Colloids Surf B Biointer 1999, 13:287-297.
56. 99mTc-ONCOFID-P] in mice using four different administration routes. J Label Compd Radiopharm 2006, 49:939-950.
57. Adams J.D., Flora K., Goldspiel B.R., Wilson J.W., Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 1993, 15:141-147.